However, one of the major obstacles in this therapy is the poor survival of transferred TILs or CTL clones, and the development of corrupted CTL memories [62,63] due to AICD and the CD4+ T cell-deficient environment, typically associated with primary cancer therapies [18,33]. This evidence concerns the gene CD4 and cancer.